CN111108211A - 工程化且完全-功能定制的糖蛋白 - Google Patents

工程化且完全-功能定制的糖蛋白 Download PDF

Info

Publication number
CN111108211A
CN111108211A CN201880056874.5A CN201880056874A CN111108211A CN 111108211 A CN111108211 A CN 111108211A CN 201880056874 A CN201880056874 A CN 201880056874A CN 111108211 A CN111108211 A CN 111108211A
Authority
CN
China
Prior art keywords
leishmania
sequence
host cell
target protein
galactosyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880056874.5A
Other languages
English (en)
Chinese (zh)
Inventor
阿米尔礼萨·法里德莫亚耶
曼纽拉·玛莉
瑞纳·福拉多尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LimmaTech Biologics AG
Original Assignee
LimmaTech Biologics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LimmaTech Biologics AG filed Critical LimmaTech Biologics AG
Priority to CN202310864838.4A priority Critical patent/CN117487873A/zh
Priority to CN202411728767.6A priority patent/CN119639577A/zh
Publication of CN111108211A publication Critical patent/CN111108211A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C12N1/105—Protozoal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/90—Protozoa ; Processes using protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01003—Glucosamine N-acetyltransferase (2.3.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01022—Lactose synthase (2.4.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201880056874.5A 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白 Pending CN111108211A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310864838.4A CN117487873A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白
CN202411728767.6A CN119639577A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527466P 2017-06-30 2017-06-30
US62/527,466 2017-06-30
PCT/EP2018/067494 WO2019002512A2 (en) 2017-06-30 2018-06-28 GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202411728767.6A Division CN119639577A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白
CN202310864838.4A Division CN117487873A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白

Publications (1)

Publication Number Publication Date
CN111108211A true CN111108211A (zh) 2020-05-05

Family

ID=62815031

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880056874.5A Pending CN111108211A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白
CN202411728767.6A Pending CN119639577A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白
CN202310864838.4A Pending CN117487873A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411728767.6A Pending CN119639577A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白
CN202310864838.4A Pending CN117487873A (zh) 2017-06-30 2018-06-28 工程化且完全-功能定制的糖蛋白

Country Status (7)

Country Link
US (2) US11913051B2 (enExample)
EP (1) EP3645732A2 (enExample)
JP (3) JP7437162B2 (enExample)
KR (2) KR20240145084A (enExample)
CN (3) CN111108211A (enExample)
AU (1) AU2018294504B2 (enExample)
WO (1) WO2019002512A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018294504B2 (en) 2017-06-30 2024-07-11 Limmatech Biologics Ag Engineered and fully-functional customized glycoproteins
WO2019234021A1 (en) 2018-06-04 2019-12-12 Limmatech Biologics Ag Glycoengineered monoclonal antibody
CN111518736B (zh) 2019-10-24 2022-04-15 华熙生物科技股份有限公司 一种高效合成高纯度透明质酸及其寡聚糖的重组谷氨酸棒状杆菌
JP7720307B2 (ja) * 2020-01-07 2025-08-07 リンマテック バイオロジクス エージー 操作されたＬｅｉｓｈｍａｎｉａ細胞
US12692472B2 (en) 2020-01-07 2026-07-28 Limmatech Biologics Ag Glycoengineering using Leishmania cells
CA3181572A1 (en) * 2020-06-08 2021-12-16 Paul STABACH Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
US20240067714A1 (en) 2020-09-14 2024-02-29 Limmatech Biologics Ag Fab sialylation of antibodies
AU2022246021A1 (en) 2021-03-23 2023-10-05 Glycoera Ag Glycan-mediated protein degradation
WO2022200388A1 (en) 2021-03-23 2022-09-29 Glycoera Ag Mannose 3 glycan-mediated protein degradation
WO2022229854A1 (en) * 2021-04-29 2022-11-03 Novartis Ag Hypersialylating cells
JP2025534987A (ja) 2022-09-28 2025-10-22 グリコエラ アーゲー グリカン媒介タンパク質分解
WO2024147113A1 (en) 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof
JP2026501773A (ja) 2023-01-05 2026-01-16 グリコエラ アーゲー 免疫グロブリンａを標的とする糖鎖改変ポリペプチド及びそれを含む複合体
WO2024147111A1 (en) 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-neutrophil autoantibodies and uses thereof
WO2024218743A1 (en) 2023-04-21 2024-10-24 Glycoera Ag Multi-functional molecules comprising glycans and uses thereof
WO2025215516A1 (en) 2024-04-08 2025-10-16 Glycoera Ag Glycoengineered polypeptides targeting igg4 autoantibodies and uses thereof
WO2025226309A1 (en) * 2024-04-26 2025-10-30 Rock Biomedical Inc. Engineered glycoprotein population and uses thereof
CN122188970B (zh) * 2026-05-18 2026-07-28 湖南福来格生物技术有限公司 一种cmp-唾液酸合成酶突变体、多核苷酸、载体、基因工程菌及突变体在唾液酸乳糖合成中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484585A (zh) * 2006-05-05 2009-07-15 格利科菲公司 在低等真核生物中生产唾液酸化n-聚糖
CN101960017A (zh) * 2008-01-03 2011-01-26 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
CN104471053A (zh) * 2011-10-28 2015-03-25 默沙东公司 用于在缺少alg3表达的巴斯德毕赤酵母株中提高n-聚糖占据并减少杂合n-聚糖的产生的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1997901A (en) * 1999-11-05 2001-05-14 Jena Bioscience Gmbh Protein expression systems for non-pathogenic kinetoplastidae
EP1878747A1 (en) * 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
JP5652206B2 (ja) 2008-10-01 2015-01-14 旭硝子株式会社 宿主、形質転換体およびその製造方法、ならびにｏ−グリコシド型糖鎖含有異種蛋白質の製造方法
EP3384018A1 (en) 2015-11-30 2018-10-10 Limmatech Biologics AG Methods of producing glycosylated proteins
AU2018294504B2 (en) 2017-06-30 2024-07-11 Limmatech Biologics Ag Engineered and fully-functional customized glycoproteins
US12692472B2 (en) 2020-01-07 2026-07-28 Limmatech Biologics Ag Glycoengineering using Leishmania cells
JP7720307B2 (ja) 2020-01-07 2025-08-07 リンマテック バイオロジクス エージー 操作されたＬｅｉｓｈｍａｎｉａ細胞
US20240067714A1 (en) 2020-09-14 2024-02-29 Limmatech Biologics Ag Fab sialylation of antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484585A (zh) * 2006-05-05 2009-07-15 格利科菲公司 在低等真核生物中生产唾液酸化n-聚糖
CN101960017A (zh) * 2008-01-03 2011-01-26 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
CN104471053A (zh) * 2011-10-28 2015-03-25 默沙东公司 用于在缺少alg3表达的巴斯德毕赤酵母株中提高n-聚糖占据并减少杂合n-聚糖的产生的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMJAD HAYAT KHAN 等: ""Humanizing glycosylation pathways in eukaryotic expression systems"", 《WORLD J MICROBIOL BIOTECHNOL》, vol. 33, pages 1 - 12, XP036125448, DOI: 10.1007/s11274-016-2172-7 *
CHRISTOPH GEISLER 等: ""Engineering 1, 4-galactosyltransferase I to reduce secretion andenhance N-glycan elongation in insect cells"", 《JOURNAL OF BIOTECHNOLOGY》, vol. 193, pages 52 - 65, XP055380212, DOI: 10.1016/j.jbiotec.2014.11.013 *
JENNIFER L CZLAPINSKI 等: ""Synthetic glycobiology: exploits in the Golgi compartment"", 《CURRENT OPINION IN CHEMICAL BIOLOGY》, vol. 10, pages 645 *

Also Published As

Publication number Publication date
US20210332403A1 (en) 2021-10-28
JP2020530273A (ja) 2020-10-22
JP2026067872A (ja) 2026-04-21
CN119639577A (zh) 2025-03-18
KR102711998B1 (ko) 2024-10-04
US20240287568A1 (en) 2024-08-29
CN117487873A (zh) 2024-02-02
US11913051B2 (en) 2024-02-27
JP2023134519A (ja) 2023-09-27
KR20240145084A (ko) 2024-10-04
WO2019002512A2 (en) 2019-01-03
EP3645732A2 (en) 2020-05-06
AU2018294504B2 (en) 2024-07-11
AU2018294504A1 (en) 2020-01-23
KR20200022486A (ko) 2020-03-03
WO2019002512A3 (en) 2019-02-28
JP7437162B2 (ja) 2024-02-22

Similar Documents

Publication Publication Date Title
US20240287568A1 (en) Engineered and Fully-Functional Customized Glycoproteins
US20240167069A1 (en) Sialylated Glycoproteins
JP7684310B2 (ja) Ｌｅｉｓｈｍａｎｉａ細胞を使用する糖鎖修飾改変
JP7720307B2 (ja) 操作されたＬｅｉｓｈｍａｎｉａ細胞
EP2971030B1 (en) Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes
CN108779443A (zh) 产生糖基化蛋白的方法
WO2019234021A1 (en) Glycoengineered monoclonal antibody
WO2024068768A9 (en) Glycoengineering using leishmania cells
EP2996772A1 (en) Methods for the treatment of neurodegeneration
US12516361B2 (en) Genetically engineered eukaryotic cells producing sialylated glycoproteins
HK1221681B (en) Methods for the treatment of neurodegeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200505